Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized and parallel controlled trial design of comparing the new treatment group of Roxadustat combined with Sacubitril Valsartan Sodium Tablets with the traditional treatment group of recombinant human erythropoietin (EPO) combined with ACEI or ARB in Chinese patients with cardiorenal anemia syndrome.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Affiliated Hospital of Qingdao University
• Treatments: Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Inclusion Criteria:

• diagnosed as regular dialysis patients with cardiorenal anemia syndrome

• Hemoglobin 60-110g / L (twice with an interval of at least 4 days);

• Volunteered to participate

Exclusion Criteria:

• Anemia caused by diseases other than CKD

• Malignant tumors

• Active liver disease

• Rheumatic immune diseases in active stage

• Hereditary or idiopathic angioedema

• Systolic blood pressure≥180 mmHg;diastolic blood pressure≥110 mmHg

• Acute myocardial infarction and unstable angina pectoris

• Severe parathyroidism

• Active peptic ulcer

• taking aliskiren

• Mental disease

• Alcohol and drug abuse

• Allergy to test drugs